Download MendeleyGermline-targeting HIV-1 Env vaccination induces VRC01-class antibodies with rare insertions.
Caniels, T.G., Medina-Ramirez, M., Zhang, J., Sarkar, A., Kumar, S., LaBranche, A., Derking, R., Allen, J.D., Snitselaar, J.L., Capella-Pujol, J., Sanchez, I.D.M., Yasmeen, A., Diaz, M., Aldon, Y., Bijl, T.P.L., Venkatayogi, S., Martin Beem, J.S., Newman, A., Jiang, C., Lee, W.H., Pater, M., Burger, J.A., van Breemen, M.J., de Taeye, S.W., Rantalainen, K., LaBranche, C., Saunders, K.O., Montefiori, D., Ozorowski, G., Ward, A.B., Crispin, M., Moore, J.P., Klasse, P.J., Haynes, B.F., Wilson, I.A., Wiehe, K., Verkoczy, L., Sanders, R.W.(2023) Cell Rep Med 4: 101003-101003
- PubMed: 37044090
- DOI: https://doi.org/10.1016/j.xcrm.2023.101003
- Primary Citation of Related Structures:
8E1P - PubMed Abstract:
Targeting germline (gl-) precursors of broadly neutralizing antibodies (bNAbs) is acknowledged as an important strategy for HIV-1 vaccines. The VRC01-class of bNAbs is attractive because of its distinct genetic signature. However, VRC01-class bNAbs often require extensive somatic hypermutation, including rare insertions and deletions. We describe a BG505 SOSIP trimer, termed GT1.2, to optimize binding to gl-CH31, the unmutated common precursor of the CH30-34 bNAb lineage that acquired a large CDRH1 insertion. The GT1.2 trimer activates gl-CH31 naive B cells in knock-in mice, and B cell responses could be matured by selected boosting immunogens to generate cross-reactive Ab responses. Next-generation B cell sequencing reveals selection for VRC01-class mutations, including insertions in CDRH1 and FWR3 at positions identical to VRC01-class bNAbs, as well as CDRL1 deletions and/or glycine substitutions to accommodate the N276 glycan. These results provide proof of concept for vaccine-induced affinity maturation of B cell lineages that require rare insertions and deletions.
Organizational Affiliation:
Department of Medical Microbiology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands; Amsterdam Institute for Infection and Immunity, Infectious Diseases, Amsterdam, the Netherlands.
